Intermittent administration of brain-derived neurotrophic factor (BDNF) ameliorates glucose metabolism and prevents pancreatic exhaustion in diabetic mice

被引:67
作者
Yamanaka, Mitsugu [1 ]
Itakura, Yasushi [2 ]
Ono-Kishino, Michiko [1 ]
Tsuchida, Atsushi [1 ]
Nakagawa, Tsutomu [1 ]
Taiji, Mutsuo [1 ]
机构
[1] Dainippon Sumitomo Pharm Co Ltd, Pharmacol Res Labs, Discovery Pharmacol 1, Konohana Ku, Osaka 5540022, Japan
[2] Daimppon Sumitomo Pharma Co Ltd, Mkt Management, Prod Strategy Grp, Chuo Ku, Tokyo 1048356, Japan
关键词
brain-derived neurotrophic factor (BDNF); obese diabetic mice (db/db); blood glucose; intermittent administration;
D O I
10.1263/jbb.105.395
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 [微生物学]; 0836 [生物工程]; 090102 [作物遗传育种]; 100705 [微生物与生化药学];
摘要
We previously demonstrated that repetitive administration of brain-derived neurotrophic factor (BDNF) ameliorates glucose metabolism and energy expenditure in obese diabetic db/db mice. However, we have not evaluated in detail the effect of single or intermittent BDNF administration on glucose metabolism in 2 diabetic animal model. The objectives of this study were to examine the dose-response effect and dosing interval of BDNF administration in db/db mice and to evaluate the effect of intermittent BDNF administration on pancreatic function in db/db mice. We evaluated the dose-response effect of BDNF by single administration in db/db mice. First, single administration of BDNF greater than 70 mg/kg significantly reduced blood glucose concentration one day after administered, and the BDNF effect was maintained for 6 d. Next, the effects of BDNF administered twice a week at 4, 10, 25, and 62.5 mg/kg on blood glucose concentration, and the effects of BDNF administered once a week at 10, 20, 30, 50, and 70 mg/kg on blood glucose concentration were examined in db/db mice. In the intermittent treatment studies, BDNF dose-dependently ameliorated glucose metabolism by not only the twice-a-week administration but also the once-a-week administration. Lastly, because BDNF reduces the food intake of obese hyperphagic diabetic mice, the effects of BDNF administered once or twice a week on the blood glucose concentration and plasma and pancreatic insulin concentrations in db/db mice were compared with those of the vehicle under pair-fed conditions. Under pair-fed conditions, the intermittent administration of BDNF (25 mg/kg, twice a week, or 50 mg/kg, once a week) significantly reduced the blood glucose concentration and increased the plasma and pancreatic insulin concentrations compared with those in the pair-fed vehicle-treated db/db mice. This indicates that the prolonged hypoglycemic effect of BDNF is not simply due to the reduction of food intake. In conclusion, we demonstrated that the intermittent administration of BDNF ameliorates glucose metabolism and prevents pancreatic exhaustion in obese diabetic mice. These findings indicate that BDNF may have potential as a unique hypoglycemic agent for the treatment of diabetes at a fundamental level with good patient compliance.
引用
收藏
页码:395 / 402
页数:8
相关论文
共 41 条
[1]
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study [J].
Aronoff, S ;
Rosenblatt, S ;
Braithwaite, S ;
Egan, JW ;
Mathisen, AL ;
Schneider, RL .
DIABETES CARE, 2000, 23 (11) :1605-1611
[2]
NEUROTROPHIC FACTORS AND THEIR RECEPTORS [J].
BARBACID, M .
CURRENT OPINION IN CELL BIOLOGY, 1995, 7 (02) :148-155
[3]
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: Binding and activation correlate with antidiabetic actions in db/db mice [J].
Berger, J ;
Bailey, P ;
Biswas, C ;
Cullinan, CA ;
Doebber, TW ;
Hayes, NS ;
Saperstein, R ;
Smith, RG ;
Leibowitz, MD .
ENDOCRINOLOGY, 1996, 137 (10) :4189-4195
[4]
PATHOGENESIS OF NIDDM - A BALANCED OVERVIEW [J].
DEFRONZO, RA ;
BONADONNA, RC ;
FERRANNINI, E .
DIABETES CARE, 1992, 15 (03) :318-368
[5]
Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion [J].
Emilsson, V ;
Liu, YL ;
Cawthorne, MA ;
Morton, NM ;
Davenport, M .
DIABETES, 1997, 46 (02) :313-316
[6]
CHARACTERIZATION OF NEW ORAL ANTIDIABETIC AGENT CS-045 - STUDIES IN KK AND OB OB MICE AND ZUCKER FATTY RATS [J].
FUJIWARA, T ;
YOSHIOKA, S ;
YOSHIOKA, T ;
USHIYAMA, I ;
HORIKOSHI, H .
DIABETES, 1988, 37 (11) :1549-1558
[7]
Brain-derived neurotrophic factor modulates glucagon secretion from pancreatic alpha cells: its contribution to glucose metabolism [J].
Hanyu, O ;
Yamatani, K ;
Ikarashi, T ;
Soda, S ;
Maruyama, S ;
Kamimura, T ;
Kaneko, S ;
Hirayama, S ;
Suzuki, K ;
Nakagawa, O ;
Nawa, H ;
Aizawa, Y .
DIABETES OBESITY & METABOLISM, 2003, 5 (01) :27-37
[8]
Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus [J].
Henry, RR .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (01) :97-103
[9]
IKEDA H, 1990, ARZNEIMITTEL-FORSCH, V40-1, P156
[10]
Effects of troglitazone - A new hypoglycemic agents in patients with NIDDM poorly controlled by diet therapy [J].
Iwamoto, Y ;
Kosaka, K ;
Kuzuya, T ;
Akanuma, Y ;
Shigeta, Y ;
Kaneko, T .
DIABETES CARE, 1996, 19 (02) :151-156